Table 3.

Tumour related overall survival of the entire patient cohort without 30-day-mortality (n = 1072) and of patients that were R0 after gastrectomy and D2-lymphadenectomy, stratified for the three time periods of treatment

Follow up of patients w/o 30d-mortality of operated patients (n = 1072)
	Time period I	Time period II	Time period III	p-value*
	(1986–1994)	(1995–2003)	(2004 – 2013)
Mean follow up time (months)	45,3	41,5	25,0	<0.001	36.9
	(0 – 257.97)	(0–212.99)	(0–111.97)		(0 – 257.97)
Median overall survival [months]	21.9 (±4.36)	21.0 (±2.27)	32.4 (±5.75)	0.037	25.2 (±2.20)
2y-survival rate [SE], n (Patients at risk)	49.7%	47.2%	57.3%	<0.007	51.4%
	(±2.8) n = 148	(±2.8),n = 143	(±2.9) n = 148		(±1.6) n = 439
5y-survival rate [SE], n (Patients at risk)	36.5%	35.1%	41.6% (±3.2)	<0.043	37.8% (±1.7)
	(±2.8) n = 88	(±2.7) n = 95	n = 46		n = 229
10y-survival rate [SE], n (Patients at risk)	33.8% (±2.8) n = 68	29.7% (±2.7) n = 45	38.5% (±3.4) n = 50	< 0.037	33.4% (±1.7), n = 113
Follow up after RO resection (w/o 30d mortality, n = 550)
Mean follow up time [months]	83.1 (1.02 – 257.97)	66.4 (1.02 – 212.99)	34.7 (1.0 - 111.97)		58.8 (1.02 – 257.97)
Median overall survival (months)	Not reached	Not reached	Not reached		Not reached
75% survival [months]	47.0 (±5.7)	28.0 (±5.7)	33.0 (±7.0)	0.313	34.3 (±4.1)
2y-survival rate [SE], n (Patients at risk)	86.9% (±2.8)	79.5% (±3.1)	83.6% (±2.9)	0.188	83.2% (±1.7)
	n = 119	n = 129	n = 124		n = 372
5y-survival rate (SE), n (Patients at risk)	68.7% (±4.0)	61.9% (±3.9)	68.7% (±4.0)	0.340	65.7% (±2.3)
	n = 78	n = 90	n = 42		n = 210
10y-survival rate (SE), n (Patients at risk)	61.9% (±4.4)	54.3% (±4.1)	--	0.270	59.0% (±2.6)
	n = 60	n = 44			n = 104
metaPC (general)	10.5% (±2.8)	16.1% (±3.1)	18.9% (±3.3)	0.074	15.5% (±1.8)
	n = 13	n = 23	n = 28		n = 64
Recurrence	49.5% (±6.7)	46.4% (±4.0)	38.2% (±4.4)	0.523	49.6% (±5.4)
	n = 59	n = 74	n = 55		n = 188